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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the efficacy of inhaled corticosteroids in reducing the severity of cough in children with sub-acute cough (defined as cough
duration of two to four weeks).
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B A C K G R O U N D
Cough is themost common symptompresenting to primary health
care services in Australia (Britt 2009) and worldwide (Cherry
2008; Irwin 2006a). The symptom of cough is also one of the
most frequent reasons for referrals to paediatricians and respiratory
physicians (Chang 2006a). In the United States, the number of
doctor visits per year for cough exceeds 27 million (Cherry 2008).
Cough accounts for 6.8 of every 100 visits to general practitioners
in Australia (Britt 2009). Cough in children is not only a common
problem, but one that impacts at both an individual level with
reduced quality of life (Marchant 2008), as well as at a population
level due to the considerable expense of treatment (Irwin 2006a).
Irrespective of the aetiology or cough duration, the symptom of
cough in children is associated with significant morbidity to par-
ents (Cornford 1993; Fuller 1998) and children as it disrupts usual
daily activities including school and sleep (Faniran 1998). Cough
was the most common reason for school absenteeism in a com-
munity-based study (Doull 1996). In the United States, 1 in 10
children receive medication for their acute cough at any one time
(Vernacchio 2008). This reflects the anxiety and distress to parents
caused by the symptom of cough in their child (Cornford 1993).
The use of unnecessary or inappropriate medications for cough is
associated with adverse effects (Thomson 2002).
Description of the condition
Cough duration is variably defined. In the Australian and United
States paediatric cough guidelines, sub-acute cough is defined as
cough lasting two to four weeks (Chang 2006a, Chang 2006b).
Acute cough in children is defined as cough lasting less than two
weeks, with chronic cough defined as cough duration longer than
four weeks (Chang 2006a). The paediatric definitions are different
to the adult definitions (with chronic cough defined as cough
lasting longer than eight weeks), due to the natural history of acute
upper respiratory tract infections in children (Hay 2002) and the
knowledge that cough in children differs from cough in adults
(Chang 2006b; Chang 2005). Cough related to an acute upper
respiratory tract infection resolves within one to three weeks in
most pre-school aged children presenting to primary care, however
cough persists for three to four weeks following an acute upper
respiratory tract infection in 10 percent of children (Hay 2002).
Description of the intervention
Corticosteroids are a commonly used medication for eosinophilic
dominated airway diseases like asthma. For asthma, oral corticos-
teroids are used predominantly during periods of exacerbations,
while inhaled corticosteroids (ICS) are used mainly for mainte-
nance or preventative therapy (BTS 2008). In children, ICS can
be delivered via a metered dose inhaler (MDI) with or without a
spacer, dry powder inhalation (DPI) or through nebulisation.
How the intervention might work
Short term treatment with ICS reduces cough frequency in adults
with post-infectious cough (Gillissen 2007). Cough is the domi-
nant symptom of airway inflammation, and airway hyper-reactiv-
ity is also associated with cough (Nair 2010). ICS can ameliorate
airway inflammation and airway hyper-reactivity (at least in some
people) (Rytila 2008), thus ICS treatment can potentially reduce
the severity of cough in children with sub-acute cough.
Why it is important to do this review
ICS is recommended as an empirical treatment in guidelines on
adults with chronic cough (Irwin 2006b). Although ICS is not
recommended in children with isolated chronic cough (i.e. cough
without any other symptoms) (Chang 2006b), many doctors con-
tinue to use ICS in children with cough of various durations. Ev-
idence examining the use of ICS for chronic cough has been ad-
dressed in a Cochrane systematic review (Tomerak 2005) and a
Cochrane review examining the use of ICS for acute cough (cough
duration less than two weeks) is in preparation. Although physi-
cians often think “it’s only a cough”, the symptom of cough is
burdensome and substantially reduces the quality of life of par-
ents (Marchant 2008). Due to the significant impact of cough in
children, improvement from ICS treatment and other therapies
would be beneficial. However as with all interventions, adverse
events will also need to be considered. A systematic review of the
benefits (or otherwise) of ICS on sub-acute cough would therefore
be useful to help guide clinical practice.
O B J E C T I V E S
To evaluate the efficacy of inhaled corticosteroids in reducing the
severity of cough in children with sub-acute cough (defined as
cough duration of two to four weeks).
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials comparing inhaled corticosteroids
with a control group for treatment of sub-acute cough in children.
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Types of participants
Children with sub-acute cough (cough duration of two to four
weeks).
Exclusion criteria: Participants with known chronic respiratory
disease (such as cystic fibrosis, asthma, bronchiectasis, aspiration
lung disease). Children with cough post acute respiratory infec-
tions such as croup will not be excluded.
Types of interventions
All randomised controlled comparisons of any type of ICS (MDI,
DPI or nebulised). Trials comparing two or more medications
without a placebo comparison group will not be included. Trials
that include the use of other medications or interventions will only
be included if all participants had equal access to such medications
or interventions.
Types of outcome measures
Reporting of one or more outcomes of interest will not be an
inclusion criteria.
Primary outcomes
Attempts will be made to obtain data on at least one of the fol-
lowing outcome measures:
Primary outcome:
1. Proportion of participants who were not cured or not
substantially improved (> 70% reduction in cough severity
measure) at follow up (clinical failure)
The following hierarchy of assessment measures for cough sever-
ity will be used (i.e. where two or more assessment measures are
reported in the same study, the outcome measure that is listed first
in the hierarchy will be used):
1. Objective measurements of cough indices (cough
frequency, cough receptor sensitivity)
2. Symptomatic (Quality of life, Likert scale, visual analogue
scale, level of interference of cough, cough diary) - assessed by
the patient (child)
3. Symptomatic (Quality of life, Likert scale, visual analogue
scale, level of interference of cough, cough diary) - assessed by
the parents/carers
4. Symptomatic (Likert scale, visual analogue scale, level of
interference of cough, cough diary) - assessed by clinicians
Secondary outcomes
1. Proportion of participants who were not cured at follow up
2. Proportion of participants who were not substantially
improved at follow up
3. Mean difference in cough indices (cough diary, cough
frequency, cough scores, quality of life)
4. Proportion of participants experiencing adverse effects of
the intervention
5. Proportion of participants experiencing complications (e.g.
requirement for medication change)
The same hierarchy of assessment measures for cough severity will
be used for secondary outcomes one and two.
Search methods for identification of studies
Electronic searches
Randomised controlled trials will be identified using theCochrane
Airways Group Specialised Register of trials, which is derived
from systematic searches of bibliographic databases including the
Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, EMBASE, CINAHL, AMED and PsycINFO, and
handsearching of respiratory journals andmeeting abstracts (please
see the Airways Group Module for further details).
All records in the Specialised Register coded as ’cough’ will be
searched using the following terms:
((steroid* or corticosteroid* or glucocorticosteroid* or glucocorti-
coid* or corticoid*) AND (inhal*)) or (beclomethasone or budes-
onide or fluticasone or ciclesonide or mometasone or flunisolide
or mometasone)
Additional searches ofCENTRAL,MEDLINEandEMBASEwill
also be conducted. The proposed search strategy for CENTRAL is
in Appendix 1. This will be adapted for use in the other databases.
Searching other resources
We will handsearch references from identified papers and reviews
for further references. We will contact authors to request their
identification of any unpublished or missed trials.
Data collection and analysis
Selection of studies
Two review authors (SA, AC) will independently assess for inclu-
sion all the potential studies we identify as a result of the search
strategy. We will resolve any disagreement through discussion or,
if required, adjudication by a third reviewer (KO).
Data extraction and management
We will review trials that satisfy the inclusion criteria and record
the following information: study setting, year of study, source of
funding, participant recruitment details (including number of el-
igible people), inclusion and exclusion criteria, other symptoms,
randomisation and allocation concealment method, number of
participants randomised, blinding (masking) of participants, care
providers and outcome assessors, duration of intervention, co-in-
terventions, number of participants not followed up, reasons for
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withdrawals from study protocol (clinical, side-effects, refusal and
other), details on side-effects of therapy, andwhether intention-to-
treat analyses were possible. We will extract data for the outcomes
described above and we will seek any follow-up data provided in
following four weeks post intervention. We will request further
information from the authors where required.
Assessment of risk of bias in included studies
Two review authors (SA, AC) will independently assess risk of
bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2008).
Any disagreement will be resolved by discussion or by involving
a third assessor. We will assess the risk of bias according to the
following domains:
1. Allocation sequence generation
2. Concealment of allocation
3. Blinding of participants and investigators
4. Incomplete outcome data
5. Selective outcome reporting
We will also note other sources of bias. Each potential source of
bias will be graded as yes, no or unclear, relating to whether the
potential for bias was low, high or unknown respectively.
Measures of treatment effect
An initial qualitative comparison of all the individually analysed
studies will examine whether pooling of results (meta-analysis) is
reasonable. We will take into account differences in study popula-
tions, inclusion and exclusion criteria, interventions and outcome
assessment. The results from studies that meet the inclusion cri-
teria and report any of the outcomes of interest will be included
in the subsequent meta-analyses.
For the dichotomous outcome variables of each individual study,
wewill calculate the odds ratio (OR) and 95%confidence intervals
(CIs) using amodified intention-to-treat analysis (modified if there
are missing values due to drop outs). We will use the Cochrane
statistical package Review Manager 5. Numbers needed to treat
(NNT) will be calculated from the pooled OR and its 95% CI
applied to a specified baseline risk (from the control group) using
an online calculator (Cates 2003).
For continuous outcomeswewill calculate themeandifference and
95%CIs usingReviewManager 5. If studies report outcomes using
different measurement scales, the standardised mean difference
will be estimated.
Unit of analysis issues
Cross-over trials are not appropriate for this intervention duration
and thus will not be included in any meta-analysis but will be
described in the text.
Dealing with missing data
We will contact investigators or study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
data where possible.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
trials in each analysis. If we identify substantial heterogeneity we
will explore it by using pre-specified subgroup analysis. We will
describe any heterogeneity between the study results and test this
to see if it reached statistical significance using the chi-squared test.
We will consider heterogeneity to be significant when the P value
is less than 0.10 (Higgins 2008). We will categorise heterogeneity
such that a value of under 25% is considered low, around 50% is
considered moderate and over 75% is considered a high degree of
heterogeneity.
Assessment of reporting biases
Where we suspect reporting bias (see ’Selective reporting bias’
above), we will attempt to contact study authors asking them to
provide missing outcome data. Where this is not possible, and the
missing data are thought to introduce serious bias, the impact of
including such studies in the overall assessment of results will be
explored by a sensitivity analysis.
If combination of data andmeta-analysis (with at least five studies)
is possible, we will assess publication bias using a funnel plot. We
will try and identify and report on any selective reporting in the
included trials, ideally by comparing the trial protocol with the fi-
nal published paper, but alternatively by comparing the ’Methods’
and ’Results’ sections of the published studies.
Data synthesis
We will determine the summary OR and mean differences with
their 95% CIs using a fixed-effect model. We will use a random-
effects model whenever there are concerns about statistical hetero-
geneity.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses (for the primary
outcome):
1. Type of control arm (placebo/no treatment)
2. Children in different age groups (younger than 6 years, 6 to
14 years and 15 years and above) (as older children are more
likely to have adult-like cough responses)
3. Doses of ICS (low to moderate defined as < 800 µg/day
budesonide equivalent versus high defined as > 800 µg/day
budesonide equivalent)
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Sensitivity analysis
Sensitivity analyses are also planned to assess the impact of the
potentially important factors on the overall outcomes:
1. Variation in the inclusion criteria
2. Risk of bias in the included studies (i.e. double versus single
blinded or unblinded; allocation clearly concealed versus unclear
or no concealment)
3. Analysis using random-effects model
4. Analysis by “treatment received” or “intention-to-treat”
5. Nebulised ICS versus metered dose inhalers
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Cough explode all trees
#2 cough*
#3 (#1 OR #2)
#4 MeSH descriptor Adrenal Cortex Hormones explode all trees
#5 (steroid* or corticosteroid* or glucocorticosteroid* or glucocorticoid* or corticoid*) AND (inhal*)
#6 beclomethasone or budesonide or fluticasone or ciclesonide or mometasone or flunisolide or mometasone
#7 (#4 OR #5 OR #6)
#8 (#3 AND #7)
#9 paediatric* or pediatric* or child* or adolescen* or infant* or young* or preschool* or pre-school* or newborn* or new-born* or
neonat* or neo-nat*
#10 MeSH descriptor Child explode all trees
#11 MeSH descriptor Pediatrics explode all trees
#12 MeSH descriptor Infant explode all trees
#13 MeSH descriptor Adolescent explode all trees
#14 (#9 OR #10 OR #11 OR #12 OR #13)
#15 (#8 AND #14)
H I S T O R Y
Protocol first published: Issue 12, 2010
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C O N T R I B U T I O N S O F A U T H O R S
SA and AC wrote the protocol, based on our previous protocols. Both will select articles from the search. SA and JM will double
enter data (if available). SA, JM and AC will draft the manuscript. KO, JA and CT reviewed the protocol and will comment on the
manuscript.
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